Literature DB >> 14706725

Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder.

Ronald Bottlender1, Tetsuya Sato, Nikolaus Kleindienst, Anton Strauss, Hans Jürgen Möller.   

Abstract

BACKGROUND: Case observations imply that depressed patients with mixed features are of high risk for maniform switch during acute treatment.
METHODS: The medical records of 158 bipolar I depressives were examined with respect to mixed depressive features at admission, naturalistic medications, and maniform switch during inpatient treatment.
RESULTS: Besides pharmacological variables, the number of mixed depressive symptoms (flight of ideas, racing thoughts, logorrhea, aggression, excessive social contact, increased drive, irritability, and distractibility) at admission was associated with a higher risk for, and the acceleration of, maniform switch during inpatient treatment. LIMITATIONS: This was a retrospective study in patients receiving naturalistic treatment. The cohort was hospital based and thus not representative of the full range of bipolar affective disorder.
CONCLUSIONS: In line with recent studies, our results underline the factors inherent in subjects at a higher risk of switch. Investigation of the relationships between several inherent factors and their interactions with pharmacological treatments may be important in resolving the controversy surrounding antidepressant-induced mania. Further validation studies on mixed depression are warranted.

Entities:  

Mesh:

Year:  2004        PMID: 14706725     DOI: 10.1016/s0165-0327(02)00265-3

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  13 in total

Review 1.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

2.  Gender differences in bipolar-II disorder.

Authors:  Franco Benazzi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-05       Impact factor: 5.270

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

4.  The continuum/spectrum concept of mood disorders: is mixed depression the basic link?

Authors:  Franco Benazzi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-09-07       Impact factor: 5.270

Review 5.  The significance of mixed states in depression and mania.

Authors:  Giulio Perugi; Giuseppe Quaranta; Liliana Dell'Osso
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

Review 6.  The neurobiology of the switch process in bipolar disorder: a review.

Authors:  Giacomo Salvadore; Jorge A Quiroz; Rodrigo Machado-Vieira; Ioline D Henter; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2010-05-04       Impact factor: 4.384

Review 7.  Bipolar II disorder : epidemiology, diagnosis and management.

Authors:  Franco Benazzi
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  Avoiding drug-induced switching in patients with bipolar depression.

Authors:  Chantal Henry; Jacques Demotes-Mainard
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  The relationship of major depressive disorder to bipolar disorder: continuous or discontinuous?

Authors:  Franco Benazzi
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

Review 10.  Various forms of depression.

Authors:  Franco Benazzi
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.